GLP-1 Drugs in 2026: Ozempic and Wegovy Are Just the Beginning
By Sanna the Weaver • Tue Feb 17 2026 • Health
The GLP-1 story began with diabetes. Semaglutide — the active compound in Novo Nordisk's Ozempic and Wegovy — was approved for type 2 diabetes management in 2017. When clinical trials showed it also produced dramatic weight loss, the drug became a cultural phenomenon: shortages, waiting lists, celebrity endorsements, and a wholesale reframing of obesity from a willpower failure to a metabolic condition with an effective pharmaceutical treatment. By 2026, GLP-1 receptor agonists are no longer just about diabetes and obesity. They are becoming one of the most broadly applicable drug classes in the history of medicine. The Cardiovascular Data Changes Everything The SELECT trial, published in 2023, showed that semaglutide reduced the risk of major cardiovascular events — heart attacks and strokes — by 20% in non-diabetic patients with obesity. This was not merely a weight-loss benefit: even adjusting for the weight reduction, there appeared to be a direct cardiovascular protective effect. The FDA has approved semaglutide specifically for cardiovascular risk reduction in adults with obesity, creating a new and enormous market that extends beyond the original diabetes and weight management indications. Eli Lilly's tirzepatide (Mounjaro, Zepbound) is posting comparable cardiovascular data. Addiction, Alzheimer's, Kidney Disease The most surprising finding of the GLP-1 era is its apparent effect on addiction. Patients taking semaglutide have reported reduced cravings for alcohol, nicotine, and other substances — a finding that researchers believe reflects GLP-1 receptors in the brain's reward pathways. Clinical trials specifically investigating semaglutide for alcohol use disorder are now in Phase 3. Separately, early-stage data suggests GLP-1 drugs may slow the progression of Alzheimer's disease through mechanisms related to neuroinflammation reduction. Novo Nordisk is running dedicated Alzheimer's trials. And FLOW trial data shows semaglutide reducing kidney disease progression by 24% — an indication the FDA is expected to formally approve in 2026. "We came for the blood sugar. We stayed for the heart. And now we are learning there is almost nowhere in the body these drugs do not reach." — Harvard endocrinologist, February 2026 The Access and Cost Problem Wegovy costs approximately
,300 per month in the United States without insurance. Medicare Part D, which covers the bulk of drug costs for seniors, was prohibited by law from covering weight-loss drugs until recently — a restriction that Congress is under pressure to lift given the cardiovascular data. In the meantime, a majority of Americans who could benefit from GLP-1 drugs cannot access them affordably. Generic semaglutide is not expected until 2032 at the earliest. The gap between what GLP-1 drugs can now do clinically and who can actually receive them is the central public health challenge of the GLP-1 era.